 SAN CLEMENTE, Calif.--BUSINESS WIRE--Glaukos Corporation NYSE: GKOS, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has submitted a supplemental pre-market approval PMA application to the U.S. Food and Drug Administration FDA for the iStent infiniteTM Trabecular Micro-Bypass System. The iStent infinite is an investigational device designed for use in a st 